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EFFECT OF CYCLIC ADMINISTRATION OF CONJUGATED
EQUINE ESTROGENS ON SEBUM PRODUCTION
IN WOMEN*
PETER E. P0Cm, M.D. AND JOHN S. STRAUSS, M.D.
In the treatment of acne with estrogens, a
method commonly used in women is the admin-
istration of the estrogen for cyclic periods of
10—14 days up to the onset of menses. With
such a treatment schedule there are interval
periods of 2 or more weeks wherein no drug is
administered. Since the secretion of the se-
baceous glands, which are primarily responsible
for the inflammatory lesions in acne (1), can
be suppressed by the exogenous administration
of adequate amounts of estrogen (2, 3), it
seemed reasonable to question whether such
intermittent therapy could effect significant
sebaceous gland suppression. Therefore, the
present report will detail the results of sebum
production studies comparing 2-week and 3-
week cycles of oral administration of conju-
gated equine estrogens to women.
ItATERIALS AND METHODS
Twenty-two female subjects, age 16 to 29, com-
prised the study group ;t eight had acne of vary-
ing severity. Conjugated equine estrogens (Pre-
marin®) were administered orally in 30 separate
drug trials, ranging in duration from 19 to 24
weeks. Six subjects received 2 or 3 separate trials
involving different dose schedules. The estrogen
was administered either in 2-week cycles or in
3-week cycles. With the 3-week cycles, rnedica-
tion was begun at mid-cycle and continued for 14
days to the onset of menses. This procedure was
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repeated in subsequent cycles for the duration of
the treatment period. With this treatment sched-
ule, doses of conjugated equine estrogens, ranging
from 2.5 mg to 7.5 mg daily, were administered in
12 individual drug trials to 10 subjects. With
3-week cyclic administration, the estrogen was
started on the 5th day of menses and continued
for 21 days. On drug withdrawal, menses usually
ensued in 2 or 3 days, and medication was re-
instituted either on day 5 of menses or no later
than the 7th interval day. In the 3-week treat-
ment group, an oral progestin, medroxyprogester-
one acetate (Provera®), was concomitantly ad-
ministered in a dose of 10 mg a day in the last
5 days of each drug cycle in order to allow for
regular cyclic bleeding on withdrawal of medica-
tion. With this treatment schedule, doses of con-
jugated equine estrogens, from 125 mg to 7.5 mg
daily, were administered in 18 separate drug trials
to 15 subjects.
In each subject, sebum production measurements
were carried out with the use of a quantitative
gravimetric procedure reported by us previously(4). An average of 6 weekly sebuin measurements
were made prior to drug administration. The sub-
jects were then tested weekly during the entire pe-
riod of estrogen treatment although in a few cases
testing was done less often.
RESULTS
Table I lists the data for sebum production
in the group of 10 subjects administered various
dosages of conjugated equine estrogens in 2-
week cycles. Since sebaceous gland suppression
from estrogen, when it occurs, is often not evi-
dent until the 3rd month or more, the mean
sebum value from estrogen treatment for all the
subjects in the study was that calculated as the
average of all values obtained after the 8th
week of drug administration. A significant de-
crease in sebaceous gland activity was observed
in only 2 instances, namely subject 1 receiving
7.5 mg daily and subject 6 with 5.0 mg daily.
Subjects 3, 4, 9 and 10 had acne. There was no
improvement in their disease, as might have
been expected since sebaceous gland suppression
did not occur.
In Table II are shown the sebum production
values in the subjects administered conjugated
equine estrogens in 3-week cycles, in doses
ranging from 1.25 to 7.5 mg per day. A signifl-
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TABLE I
Sebum production (mg/b cm2/3 hr) during 2-week cyclic administration of conjugated
equine estrogens
Dose Subject
MeanpTt0t
seburn
Mean sebum, 4-week periods
1—4 5—8 9-12 13—16 17—20 21—24
Mean
treatment
se urn srn value
7.5 mg
daily
1
2
3f
4t
5
3.60
4.07
3.24
2.24
3.78
2.79
4.23
3.80
2.79
4.36
2.50
3.99
3.37
3.02
4.27
2.67
4.13
3.39
2.81
4.13
2.48
4.23
4.30
2.09
4.75
2.62
4.34
2.71
2.21
3.56
—
3.07
3.48
2.11
—
2.60
4.05
3.41
2.38
4.13
28%
None
None
None
None
<.001
—
—
—
—
5.0 mg
daily
6
7
5
4f
3.66
2.34
3.82
2.56
3.72
2.17
3.89
2.60
2.28
2.32
4.48
3.02
2.32
2.17
3.69
2.81
2.40
2.17
3.99
2.88
2.21
1.99
3.29
2.58
—
1.74
2.96
2.36
2.26
2.05
3.52
2.60
37%
12%
8%
None
<.001
NS
NS
—
2.5mg
daily
8
9t
lot
2.03
3.62
3.04
2.09
3.72
2.71
1.53
5.08
3.56
2.03
3.00
2.90
1.96
3.84
3.00
1.78
3.62
3.14
—
—
—
1.82
3.43
3.02
10%
5%
None
NS
NS
—
* Average of all sebum values after 8th week of drug administration.
t Acne.
TABLE II
Sebum production (mg/b cm2/3 hr) during 3-week cyclic administration of conjugated
equine estrogens
Dose Subject
Mean
Pr:1t:t
seburn
Mean sebum, 4-week periods
—
Mean
treatrnent
se urn PerceIt p value
1—4 5—S 9—il 13—16 17—20 21—24
7.5 mg
daily
4t
11
12
5
3.12
5.29
3.35
4.73
3.64
4.84
3.17
4.01
2.48
4.15
3.04
4.19
2.36
3.95
2.62
4.19
2.45
—
2.45
4.56
2.07
3.84
2.52
3.16
—
—
—
—
2.28
3.91
2.52
3.99
27%
26%
25%
16%
<.01
<.01
<.01
NS
5.0 mg
daily
6
7
13
l4f
15t
3.66
2.98
3.04
1.20
2.45
3.31
1.84
2.94
1.09
2.79
2.96
1.92
2.83
1.34
2.50
2.90
2.17
2.50
0.99
2.58
2.42
2.14
2.17
0.81
2.03
2.47
2.28
2.01
0.95
1.90
1.88
1.42
1.92
—
1.94
2.47
2.11
2.19
0.93
2.15
33%
29%
28%
23%
12%
<.001
<.02
<.01
<.01
NS
2.5 mg
daily
16
15f
13
17t
18t
19
4.34
2.03
2.77
5.21
3.18
2.50
3.69
2.30
2.50
5.72
3.35
1.86
3.45
1.66
3.16
6.00
3.04
1.82
3.20
1.90
2.75
5.37
3.39
2.67
3.84
1.47
2.36
4.86
3.41
2.19
3.04
1.88
2.58
4.88
2.92
2.90
—
1.66
2.17
4.34
2.71
2.09
3.35
1.78
2.52
4.95
3.14
2.50
23%
12%
9%
5%
1%
None
<.05
NS
NS
NS
NS
—
1.25 mg
daily
20
21
22
2.36
1.70
1.30
1.96
2.47
1.55
2.26
1.84
1.45
2.19
1.78
1.57
2.26
1.70
1.86
1.88
1.61
1.26
—
—
—
2.09
1.72
1.45
11%
None
None
NS
—
—
* Average of all sebum values after 8th week of drug administration.
t Acne.
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TABLE III
Comparisons of sebaceous gland responses in
individuals receiving different dose schedules
of conjugated equine estrogens
Subject Dose schedule
Per cent
SebWfl
p,eSsion
P value
4 7.5 mg; 3-week cycles
7.5 mg; 2-week cycles
5.0 mg; 2-week cycles
27%
None
None
<.01
—
—
7 5.0 mg; 3-week cycles
5.0 mg; 2-week cycles
29%
12%
<.02
NS
13 5.0 mg; 3-week cycles
2.5 mg; 3-week cycles
28%
9%
<.01
NS
6 5.0 mg; 3-week cycles
5.0 mg; 2-week cycles
33%
37%
<.001
<.001
5 7.5 mg; 3-week cycles
7.5 mg; 2-week cycles
5.0 mg; 2-week cycles
16%
None
8%
NS
—
NS
15 5.0 mg; 3-week cycles
2.5 mg; 3-week cycles
12%
12%
NS
NS
cant reduction in sebum secretion was seen in 3
out of 4 subjects receiving 7.5 mg daily, and in
4 out of 5 individuals administered 5.0 mg daily.
Only one subject (16) out of 6 demonstrated
a sebum-suppressive effect from 2.5 mg daily,
and none of the 3 subjects on 1.25 mg daily
showed a response. Five cases had acne (sub-
jects 4, 14, 15, 17, 18). In only 2 cases (subjects
4 and 14) did the acne improve, and in both in-
stances they showed a significant fall in sebum
output.
Six subjects received more than one course
of drug administration. Table III compares the
sebaceous gland responses for the various dose
schedules given to each of these subjects. It can
be seen that both the dose of drug (e.g. subject
13) and the schedule of its administration (e.g.
subjects 4 and 7) are important factors in de-
termining sebaceous gland responsiveness. It
should also be noted that relatively high doses,
whether administered in 2-week or 3-week
cycles, may fail to suppress glandular activity
(e.g. subjects 5 and 15).
DISCUSSiON
The present studies have demonstrated that a
minimum daily dose of 5.0 mg of conjugated
equine estrogens is, in essence, required for sig-
nificant suppression of sebaceous gland activity
in women. The schedule of drug administration
is also important since with drug amounts of
5.0 mg and 7.5 mg, a significant decrease in Se-
bum production was observed in 7 out of 9 sub-
jects receiving 3-week cyclic treatment but in
only 2 out of 9 receiving 2-week cyclic treat-
ment.
The observations from this investigation of
the relative ineffectiveness of 2-week cyclic ad-
ministration of oral conjugated equine estrogens
on sebaceous gland secretion lend corroboration
to the clinical studies reported by Torre and
Klumpp (5). They found that the post-ovula-
tory cyclic administration of conjugated equine
estrogens to females with acne required in the
vast majority of instances 5.0 mg or more daily
for satisfactory control of the disease. As men-
tioned previously, there were 8 patients in the
present study with acne. In only two did the
condition improve, and these were the only pa-
tients of the group with a fall in sebum produc-
tion from estrogen. There was no apparent
relationship between the response of the se-
baceous glands and the presence or absence of
acne before treatment.
Mention should be made of the effect on the
menstrual periods from the estrogen adminis-
tered to the subjects in this study. Of those re-
ceiving 3-week cyclic treatment (combined, as
described above, with an oral progestin in the
last 5 days of each drug cycle), only one, a sub-
ject taking 5.0 mg a day, experienced menstrual
difficulty consisting of 2 separate episodes of
breakthrough bleeding. By contrast, in the
group receiving 2-week cyclic drug administra-
tion, 5 out of 12 subjects noted changes in the
menstrual cycles. The menses per se were not
particularly abnormal, but the intervals be-
tween periods became decidedly irregular.
SUMMARY
Conjugated equine estrogens, in oral doses of
1.25 to 7.5 mg daily, were administered cyclically
for 2-week or 3-week periods for 19—24 weeks to
22 female subjects in 30 separate drug trials.
The purpose was to study the effect of this es-
trogen in various dose schedules on sebaceous
gland secretion. The results were as follows: 1)
in 12 trials of 2-week cyclic treatment, sebum
production was decreased significantly in only 2
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instances (dosages of 5.0 and 7.5 mg); 2) in 18
trials of 3-week cyclic treatment, a significant
reduction of sebum secretion occurred in most
subjects receiving 5.0 and 7.5 mg daily; and 3)
of eight subjects with acne, only two were im-
proved, these being the only patients among
those with acne showing significant sebaceous
gland inhibition.
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